Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Correspondence / Letter

Correspondence: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.

Pharmacological research

Citation & Authors

Pharmacol Res. 2025;213:107639.

Chang-Yuan Hsu; Che-Wei Chang; Su-Boon Yong; Chin-Yuan Yii

Abstract & Original paper

No abstract is available in the public index. Please consult the original paper.

Go to journal page